Table 1. Mechanisms relevant to oncogene and oncoprotein alterations in NSCLC.
| Authors | Samples | Histology [case load] | Factors | Characteristics with pemetrexed resistance |
|---|---|---|---|---|
| Wu SG et al. [2011] (21) | Tissue | Adenocarcinoma [296]; SCC [46]; others [23] | EGFR mutation | Negative |
| Igawa S et al. [2016] (22) | Tissue | Adenocarcinoma [53] | EGFR mutation | Exon 19 (deletion) |
| Yu Z et al. [2014] (23) | A549 cells | – | EGFR, HER3 | Upregulated |
| Lee HY et al. [2013] (26) | Tissue | Adenocarcinoma [201]; SCC [127]; others [49] | ALK rearrangements | Negative |
| Park S et al. [2015] (27) | Tissue | Adenocarcinoma [442] | ALK rearrangements | Negative |
| Lee JO et al. [2011] (28) | Tissue | Adenocarcinoma [78]; others [17] | ALK rearrangements | Negative |
| Chen YF et al. [2016] (29) | Tissue | Adenocarcinoma [253] | ROS1 translocations | Negative |
| Liang Y et al. [2015] (31) | Tissue | NSCLC [196] | RAS mutations | Negative |
| Wu MF et al. [2010] (32) | A549 & H1355 cells | – | p21, p27 | Downregulated |
| Wen Y et al. [2012] (33) | A549 cells | – | ZMAT3 | Upregulated |
| Sun JM et al. [2011] (35) | Tissue | Adenocarcinoma [255]; LCC [11]; pleomorphic carcinoma [1]; others [18] | TTF-1 | Negative |
| Grønberg BH et al. [2013] (36) | Tissue | Adenocarcinoma [112]; SCC [62]; LCC [13]; others [49] | TTF-1 | Negative |
NSCLC, non-small cell lung cancer; LCC, large-cell carcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1; ZMAT3, p53-regulated zinc finger protein; TTF-1, thyroid transcription factor 1.